NCT03752307View on ClinicalTrials.gov

Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 15, 2019

Primary Completion Date

July 6, 2023

Study Completion Date

July 6, 2023

Conditions
Multiple Sclerosis
Interventions
DRUG

Isoxsuprine Hydrochloride

Compounded Isoxsuprine hydrochloride capsules

DRUG

Placebo

Identical microcrystalline cellulose placebo manufactured to mimic Isoxsuprine Hydrochloride 10 MG capsules

DRUG

Corticosteroid

This can be any accepted regimen, including daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon

Trial Locations (1)

87106

University of New Mexico MS Specialty Clinic, Albuquerque

All Listed Sponsors
lead

University of New Mexico

OTHER

NCT03752307 - Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses | Biotech Hunter | Biotech Hunter